HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
Study Goal
The researchers aimed to evaluate the potential advantages and long-term safety of HIF stabilizers as a new strategy for treating CKD anemia, compared to traditional erythropoietin therapy and iron supplementation.
Results Summary
The study found that HIF stabilizers, a new class of drugs, effectively upregulate erythropoietin gene expression and offer advantages such as oral administration and lower circulating erythropoietin levels. However, long-term safety, particularly regarding effects on other hypoxia-sensitive genes like VEGF, remains under investigation.
Population
Adult and pediatric patients with chronic kidney disease (CKD).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
erythropoietin therapy and iron supplementation | decrease | anemia in chronic kidney disease | adult and pediatric patients with chronic kidney disease | null | has traditionally been treated with, with great success | #1 |
HIF stabilizers (HIF prolyl-hydroxylase inhibitors) | increase | erythropoietin gene expression | null | null | prevents the proteasomal degradation of HIF-α, thereby inducing upregulation | #2 |
HIF stabilizers (HIF prolyl-hydroxylase inhibitors) | no change | administration route | patients | null | is orally active | #3 |
HIF stabilizers (HIF prolyl-hydroxylase inhibitors) | decrease | erythropoietin levels | patients | null | patients are exposed to lower circulating levels | #4 |
Anemia is a common complication of chronic kidney disease (CKD) in adult and pediatric patients. It has traditionally been treated with erythropoietin therapy and iron supplementation, with great success. With the discovery of the major transcription factor hypoxia inducible factor (HIF) for the erythropoietin gene in 1992, molecules were created that inhibit the HIF prolyl-hydroxylase enzyme. This new class of drug-called HIF stabilizers, or HIF prolyl-hydroxylase inhibitors-prevents the proteasomal degradation of HIF-α, thereby inducing upregulation of the erythropoietin gene. This new strategy for treating CKD anemia is already in phase III clinical trials in adults, and the potential advantages of this therapy are that it is orally active (thereby avoiding injections), and patients are exposed to lower circulating levels of erythropoietin. The long-term safety of this strategy, however, requires elucidation in these trials, particularly since there are many other hypoxia-sensitive genes, notably, angiogenic factors such as vascular endothelial growth factors (VEGF), as well as glycolytic enzymes. As with all new therapies, it is only once a positive benefit: risk profile has been ascertained in adults that the treatment will translate across into pediatrics. Specific issues in the pediatric CKD population are discussed in this review.